In Brief: Chattem
This article was originally published in The Tan Sheet
Executive Summary
Chattem: U.S. sales increase 6% in fiscal 1995 (ended Nov. 30), led by the recently acquired pHisoderm skin care and Benzodent denture analgesic brands; a "significant gain" in Bullfrog sunscreens; and "strong demand" for Icy Hot analgesics, the firm says Jan. 26. Pamprin and Premsyn PMS menstrual products were flat and Flex-all analgesic sales were down. Chattem's international sales 14% jump was driven by pHisoderm in Canada and all major brands in Europe, the firm says. Consolidated sales rose 6.6% to $100.7 mil. in fiscal 1995. Net income was $12 mil., up from $2.1 mil. in FY 1994, and includes a $9.3 mil. gain from the disposal of the Specialty Chemicals division in May 1995. Income from operations increased 15.4% to $14.5 mil...